Literature DB >> 24343741

Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.

Hiroshi Minato1, Nozomu Kurose, Mana Fukushima, Takayuki Nojima, Katsuo Usuda, Motoyasu Sagawa, Tsutomu Sakuma, Akishi Ooi, Isao Matsumoto, Makoto Oda, Yoshihiko Arano, Junzo Shimizu.   

Abstract

OBJECTIVES: To identify useful biomarkers for differentiating between malignant mesothelioma (MM) and reactive mesothelial cells (RMCs).
METHODS: Formalin-fixed, paraffin-embedded (FFPE) tissues from 34 MM and 40 RMC samples were analyzed using immunohistochemistry, and the findings were compared.
RESULTS: Positive markers for MM included insulin-like growth factor 2 messenger RNA binding protein 3 (IMP3), glucose transporter 1 (GLUT1), epithelial membrane antigen (EMA), and CD146, which showed sensitivities of 94%, 85%, 79%, and 71% and specificities of 78%, 100%, 88%, and 98%, respectively. In sarcomatoid MM, EMA had significantly lower expression than did IMP3, GLUT1, and CD146 (P < .001). The areas under receiver operating characteristic curves were the highest for IMP3 (0.95), followed by GLUT1 (0.93). When the optimal cutoff points for IMP3 (30%) and GLUT1 (10%) were used, the sensitivity of IMP3 and GLUT1 for MM was 100%, and the specificity of both for MM was 95%.
CONCLUSIONS: The combination of IMP3 and GLUT1 is most appropriate for distinguishing MM from RMC using FFPE sections.

Entities:  

Keywords:  CD146; Desmin; EMA; GLUT1; IMP3; Immunohistochemistry; Malignant mesothelioma; Reactive mesothelial cell

Mesh:

Substances:

Year:  2014        PMID: 24343741     DOI: 10.1309/AJCP5KNL7QTELLYI

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

4.  Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Authors:  Andrew Churg; Richard Attanoos; Alain C Borczuk; Lucian R Chirieac; Françoise Galateau-Sallé; Allen Gibbs; Douglas Henderson; Victor Roggli; Valerie Rusch; Meagan J Judge; John R Srigley
Journal:  Arch Pathol Lab Med       Date:  2016-03-31       Impact factor: 5.534

5.  Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.

Authors:  Tomoyuki Hida; Shinji Matsumoto; Makoto Hamasaki; Kunimitsu Kawahara; Tohru Tsujimura; Kenzo Hiroshima; Toshiaki Kamei; Kenichi Taguchi; Akinori Iwasaki; Yoshinao Oda; Hiroshi Honda; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2015-10-15       Impact factor: 6.716

Review 6.  Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.

Authors:  Anders Hjerpe; Valeria Ascoli; Carlos Bedrossian; Mathilde Boon; Jenette Creaney; Ben Davidson; Annika Dejmek; Katalin Dobra; Ambrogio Fassina; Andrew Field; Pinar Firat; Toshiaki Kamei; Tadao Kobayashi; Claire W Michael; Sevgen Önder; Amanda Segal; Philippe Vielh
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

7.  Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia.

Authors:  Kei Kushitani; Vishwa Jeet Amatya; Amany Sayed Mawas; Rui Suzuki; Yoshihiro Miyata; Morihito Okada; Kouki Inai; Takumi Kishimoto; Yukio Takeshima
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

8.  Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.

Authors:  Yusuke Takehara; Toshiko Yamochi; Tasuku Nagumo; Tomonari Cho; Fumihiko Urushibara; Kohei Ono; Tomonori Fujii; Naoko Okamoto; Yosuke Sasaki; Sakiko Tazawa; Mayumi Honma; Tomoko Norose; Eisuke Shiozawa; Genshu Tate; Masafumi Takimoto
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

9.  Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.

Authors:  Emanuela Cova; Laura Pandolfi; Miriam Colombo; Vanessa Frangipane; Simona Inghilleri; Monica Morosini; Simona Mrakic-Sposta; Sarah Moretti; Manuela Monti; Ymera Pignochino; Silvia Benvenuti; Davide Prosperi; Giulia Stella; Patrizia Morbini; Federica Meloni
Journal:  Int J Nanomedicine       Date:  2019-01-23

10.  IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.

Authors:  Christoph Burdelski; Nilofar Jakani-Karimi; Frank Jacobsen; Christina Möller-Koop; Sarah Minner; Ronald Simon; Guido Sauter; Stefan Steurer; Till S Clauditz; Waldemar Wilczak
Journal:  Oncol Rep       Date:  2017-11-02       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.